Andrew Crockett is the founder of KalVista Pharmaceuticals. Backed by Novo A/S, SV Life Sciences, RA Capital Management. Based in Cambridge, United States.
Andrew Crockett is the Chief Executive Officer of KalVista Pharmaceuticals, a clinical-stage pharmaceutical company. The company focuses on discovering, developing, and commercializing small molecule protease inhibitors, particularly for diseases with significant unmet needs like hereditary angioedema (HAE) and diabetic macular edema (DME). The company announced on April 7, 2020, that its cash runway was extended into at least early 2022.
Full founder directory · Investor directory · Company funding database · Fundraising library